Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesReliability of a pretransplant i.v. BU test dose performed 2 weeks before myeloablative FluBu conditioning regimen
Bone Marrow Transplantation, 06/23/09
Beri R et al. - In patients who had a test dose, a significant correlation between the first and subsequent doses of BU during the conditioning regimen was observed. The findings may allow more centers to pursue transplant strategies with targeted BU by overcoming the time limitation for PK studies during the conditioning regimen.
D Rondelli, 06/23/09
| The use of targeted doses of busulfan allows us to give to every patient the right dose of chemotherapy prior to a stem cell transplant. Because busulfan pharmacokinetics studies are not performed in the majority of the hospitals, it may be difficult for many centers to arrange for these tests to be obtained within 24-48 hours. By showing that a test dose 2 weeks before transplant is reliable and does not require the doctors to receive the results within 24-48 hours we hope to facilitate the use of targeted busulfan in many transplant centers. |
Today in BMT/SCT...keeping you current
Receive free subspecialty "5-minute updates" via email
5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis
Bone Marrow Transplantation, 10/15/09
Management of relapse after allo-SCT for AML and the role of second transplantation
Bone Marrow Transplantation, 10/29/09
New advances in the treatment of acute promyelocytic leukemia
International Journal of Hematology, 10/07/09
Sponsor
Article Search
Sponsor
Sponsor